Sara J Dunaj

Title: Sara J Dunaj: Innovator in mRNA Therapy for Primary Ciliary Dyskinesia

Introduction

Sara J Dunaj is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of medical research, particularly in the treatment of primary ciliary dyskinesia (PCD). With a total of two patents to her name, her work focuses on innovative therapies that leverage mRNA technology.

Latest Patents

Sara's latest patents revolve around the composition and methods for treating primary ciliary dyskinesia. The inventions provide methods and compositions that utilize mRNA therapy to address PCD. Specifically, the compositions include an mRNA that comprises a dynein axonemal heavy chain 5 (DNAH5) coding sequence. These compositions are administered at effective doses and intervals to reduce the intensity, severity, or frequency of symptoms associated with PCD. Notably, the mRNAs are optimized to function in vivo without the need for nucleotide modifications, ensuring sustained therapeutic effects.

Career Highlights

Sara J Dunaj is associated with Translate Bio, Inc., where she continues to advance her research in mRNA therapies. Her work is pivotal in developing innovative solutions for genetic disorders, particularly those affecting respiratory function.

Collaborations

Sara collaborates with talented individuals such as Anusha Dias and Darshan Parekh, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Sara J Dunaj is a trailblazer in the field of mRNA therapy, with her inventions poised to make a significant impact on the treatment of primary ciliary dyskinesia. Her dedication to advancing medical science through innovative solutions is commendable.